PG
The Procter & Gamble Company
NYSE · Consumer Defensive · Household & Personal Products · US
$146.63
−0.20%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 87.0B | 87.0B | 84.3B | 84.0B | 82.0B |
| Cost of Revenue | 43.4B | 43.4B | 41.2B | 40.8B | 42.8B |
| Gross Profit | 43.7B | 43.7B | 43.1B | 43.2B | 39.2B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 23.9B | 23.9B | 22.7B | 23.3B | 21.1B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | 1.3B | — |
| Total Operating Expenses | 23.9B | 23.9B | 22.7B | 24.6B | 21.1B |
| Cost and Expenses | 67.3B | 67.3B | 63.8B | 65.5B | 63.9B |
| Operating Income (EBIT) | 19.7B | 19.7B | 20.5B | 18.5B | 18.1B |
| Non-Operating | |||||
| Interest Income | 430.0M | 430.0M | 469.0M | 473.0M | 307.0M |
| Interest Expense | 877.0M | 877.0M | 907.0M | 925.0M | 756.0M |
| Net Interest Income | (447.0M) | (447.0M) | (438.0M) | (452.0M) | (449.0M) |
| Other Non-Op Income/Expense | 629.0M | 629.0M | (284.0M) | 216.0M | 219.0M |
| Non-Operating Income (excl Interest) | (1.5B) | (1.5B) | (623.0M) | (1.1B) | (975.0M) |
| EBT (Pre-Tax Income) | 20.4B | 20.4B | 20.2B | 18.8B | 18.4B |
| Income Tax Expense | 4.2B | 4.2B | 4.1B | 3.8B | 3.6B |
| Bottom Line | |||||
| Net Income | 16.0B | 16.0B | 16.0B | 14.9B | 14.7B |
| Earnings from Cont. Ops | 16.1B | 16.1B | 16.1B | 15.0B | 14.7B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 16.0B | 16.0B | 16.0B | 14.9B | 14.7B |
| Per Share | |||||
| Basic EPS | $6.75 | $6.75 | $6.67 | $6.18 | $6.07 |
| Diluted EPS | $6.62 | $6.62 | $6.51 | $6.02 | $5.90 |
| Revenue Per Share | $35.93 | $35.93 | $34.34 | $35.61 | $34.63 |
| Shares | |||||
| Basic Shares Outstanding | 2.4B | 2.4B | 2.5B | 2.4B | 2.4B |
| Diluted Shares Outstanding | 2.4B | 2.4B | 2.5B | 2.5B | 2.5B |
| Profitability Metrics | |||||
| EBITDA | 21.3B | 21.3B | 23.9B | 22.6B | 21.8B |
| D&A | — | — | 2.8B | 2.9B | 2.7B |
| EBIT | 21.3B | 21.3B | 21.1B | 19.7B | 19.1B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026